




Dansk Selskab for Toksikologi & Farmakologi

## Summer meeting; Early clinical research in Denmark

Thursday, 13 June 2024, 11am-17pm

Aarhus University, Building 1252, Søauditorierne, Eduard Biermann auditorium (1252-204)  
Bartholins Allé 3, 8000 Aarhus C, Denmark

- 11.00-11.10: Welcome.** *Anders Jensen, Professor; Copenhagen University, Chair; Danish Society for Toxicology and Pharmacology.*
- 11.10-11.30: Denmark as the preferred country for early clinical trials. *Kirsten Bødker, Head of Business Relations; Trial Nation.*
- 11.30-12.15: The regulatory landscape for early phase research from the Danish authorities' perspective. *Lene Grejs Petersen, Senior Adviser, Clinical Trials; Danish Medicines Agency & Helle Christiansen, Special Adviser; Danish National Center for Ethics.*
- 12.15-13.00: Lunch**
- 13.00-13.20: First-in-human oncology trials - comprehensive genomic profiling for identifying and treating patients. *Martin Højgaard, Clinical Oncologist, Phase 1 Unit; Rigshospitalet.*
- 13.20-13.40: Establishing the Novo Nordisk Clinical Innovation Centre (CLINiC). *Camilla Wamberg, Senior Director, CLINiC; Novo Nordisk A/S & Melissa Voigt Bolten Jagd; Scientific Medical Director, CLINiC; Novo Nordisk A/S.*
- 13.40-14.00: Strengths/challenges for trials in DK – 2 case studies. *Kim Kjøller, CEO; Union Therapeutics.*
- 14.00-14.20: Advancing diabetes care: Clinical insights from Steno Diabetes Center Aarhus. *Professor Søren Gregersen, Medical Lead, Trial Unit; Steno Diabetes Center Aarhus.*
- 14.20-14.50: Nonclinical development and phase 1 of cell therapies: a Parkinsons Disease case. *Frederikke Lihme Egerod, Non-Clinical Project Director; Novo Nordisk A/S.*
- 14.50-15.20: Coffee**
- 15.20-15.40: Sanos Group - Phase 1 and Beyond; *Bernt Husøy, Chief Physician; Sanos Clinic & Casper Clemmensen, Chief Commercial Officer; Sanos Group.*
- 15.40-16.00: A phase 0 observational study supporting clinical development of CIC-1 inhibitors for the treatment of Charcot-Marie-Tooth disease – an NMD Pharma/AUH case. *Thomas Grønnebæk, Clinical scientist; NMD Pharma.*
- 16.00-16.30: Zelo phase I unit and DanTrials - a joint venture at Bispebjerg Hospital. *David Peick Sonne, Head of Zelo Phase I Unit & Torben Balchen, CEO; DanTrials.*
- 16.30-16.50: Patient perspective on early clinical trials. *Speaker to be announced.*
- 16.50-17.00: Wrap-up**



**Find your way:**

<https://www.au.dk/om/organisation/find-au/bygningskort/?os=29>

### Registration:

As we have a limited number of seats, please send an email to Charlotte ([ckhs@novonordisk.com](mailto:ckhs@novonordisk.com)) no later than 11 June 2024, for registration. Your registration will be confirmed by email.